Therapy Areas: Central Nervous System
Accord BioPharma's second pegfilgrastim biosimilar to NEULASTA approved by US FDA
10 July 2026 - Accord BioPharma, the US specialty division of India-based Intas Pharmaceuticals Ltd, focused on the development of oncology, immunology, and central nervous system (CNS) therapies, ann...
Nona Biosciences and Lonza collaborate on antibody-based BBB-crossing technology for CNS diseases
2 July 2026 - Global biotechnology company Nona Biosciences, a subsidiary of HBM Holding Limited (HKEX:02142), announced on Wednesday a strategic collaboration with Swiss pharmaceutical company Lonza ...
Silo Pharma regains compliance with Nasdaq minimum bid price
19 June 2026 - Silo Pharma (Nasdaq:SILO), a developmental-stage biopharmaceutical company involved in novel therapeutics and drug delivery systems, announced on Thursday that it has received confirmat...
Lilly acquires 4E Therapeutics to advance non-opioid chronic pain treatment
17 June 2026 - 4E Therapeutics Inc, a neuroscience company developing next-generation treatments for chronic pain, announced on Tuesday that it has been acquired by US pharmaceutical company Eli Lilly...
Bayer receives FDA approval for AMBELVIST MRI contrast agent
15 June 2026 - German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) said on Monday that it has received US Food and Drug Administration (FDA) approval for AMBELVIST (gadoqua...
Lynk Pharmaceuticals' partner Formation Bio doses first participant in BLKR201 Phase 1 trial
10 June 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, announced on Tuesday that its partner, Formation Bio, ...